KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Detection of Anti-SARS-CoV-2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID-19 Vaccine.

Mingzhu Zhu, Edmond Massuda, Urvashi Patel, Gordon Chau, Raj Kalkeri, Shane Cloney-Clark, Katherine Smith, Susan Neal, Joyce S Plested, Raburn M Mallory, Chijioke Bennett

J Med Virol 97(10) e70645

PMID41117170
PMCIDPMC12538530
DOI10.1002/jmv.70645
发表日期2025-10-21
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。
摘要

摘要

Immunoglobulin (Ig) A acts as a first line of defense against respiratory pathogens. Mucosal IgA in salivary and nasal passages has a rapid response to antigens and can play a protective role against reinfection. The mainstay for analyzing SARS-CoV-2 infection and vaccine efficacy has been assessment of serum IgG levels; however, validated assays for assessment of mucosal IgA in clinical samples are necessary as new and adapted measures are generated to combat immune-evasive viral variants. A mucosal IgA assay was developed and tested through assessment of IgA levels in salivary samples from participants of the 2019nCoV-314/NCT05973006 study. These participants had previously received ≥ 2 mRNA-based COVID-19 vaccinations prior to enrollment and received a single intramuscular study dose of NVX-CoV2601 (XBB.1.5) or bivalent vaccine (NVX-CoV2601 + NVX-CoV2373 [Wuhan]). Salivary samples were collected prior to vaccination on Day 0 and on Day 28 to assess response postvaccination. Both vaccine groups elicited a significant increase in anti-SARS-CoV-2 spike IgA against XBB.1.5. Furthermore, cross-reactivity by identification of anti-JN.1 and anti-Wuhan IgA was also observed. The detection of IgA in clinical mucosal samples using this assay will be a valuable tool in supporting vaccine development.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Anti‐rS salivary IgA levels against SARS‐CoV‐2 variant XBB.1.5, from individual clinical samples from the 2019nCoV‐314 study. IgA titers (ng/mL) to XBB.1.5 rS at Day 0 and Day 28 after vaccination with NVX‐CoV2601 or bivalent vaccine. Mean concentrations at Days 0 and 28 within each vaccine group were compared with the Wilcoxon signed rank test and p values determined. IgA, immunoglobulin A; rS, recombinant spike.
非 KM Figure
Figure 2Cross reactivity of salivary IgA to SARS‐CoV‐2 rS after immunization with NVX‐CoV2601 (XBB.1.5 vaccine) in a series of matched, pooled serum samples from the 2019nCoV‐314 study. Anti‐spike IgA concentrations against SARS‐CoV‐2, variant strains XBB.1.5 or JN.1, or Wuhan SARS‐CoV‐2 at 28 days after vaccination with NVX‐CoV2601 in pooled salivary samples from the 2019nCoV‐314 study. Samples from individuals with similar IgA concentrations (generally with elevated titers) were pooled to generate sufficient volume for this analysis and be tested across all three strains. Mean concentrations were calculated from multiple runs and more than one analyst. Mean values for QC samples are represented by dotted lines and listed on the right of each graph. GMT, geometric mean titer; IgA, immunoglobulin A; rS, recombinant spike; QC, quality control.
非 KM Figure